{"id":"vonoprazan-amoxicillin-levofloxacin","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the H+/K+ ATPase enzyme, vonoprazan reduces gastric acid secretion, which can help alleviate symptoms of gastroesophageal reflux disease (GERD). This mechanism is distinct from traditional proton pump inhibitors (PPIs), which also inhibit gastric acid secretion but through a different mechanism. Vonoprazan's P-CAB mechanism may offer improved efficacy and reduced side effects compared to PPIs.","oneSentence":"Vonoprazan is a potassium-competitive acid blocker (P-CAB) that inhibits gastric acid secretion by blocking the H+/K+ ATPase enzyme.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:48.262Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of gastroesophageal reflux disease (GERD)"},{"name":"Eradication of Helicobacter pylori"}]},"trialDetails":[{"nctId":"NCT07179159","phase":"NA","title":"Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial","status":"RECRUITING","sponsor":"Yanqing Li","startDate":"2025-09-09","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":372},{"nctId":"NCT07344506","phase":"PHASE4","title":"CURE-H. Pylori: A Trial on the Combination of Anti-Ulcerants and Levofloxacin-Based Therapy for Helicobacter Pylori Eradication","status":"RECRUITING","sponsor":"Dow University of Health Sciences","startDate":"2025-05-01","conditions":"H. Pylori Gastrointestinal Disease, H.Pylori Infection, H.Pylori Eradication Rate","enrollment":942},{"nctId":"NCT07040839","phase":"PHASE4","title":"Comparison of Omeprazole vs Vonoprazon in Treatment of H Pylori Infection","status":"NOT_YET_RECRUITING","sponsor":"Rehman Medical Institute - RMI","startDate":"2025-07","conditions":"H Pylori","enrollment":128},{"nctId":"NCT06414707","phase":"PHASE3","title":"Efficacy of Vonoprazan in Eradication of Resistant Strain of Helicobacter Pylori","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-10-12","conditions":"Helicobacter Pylori Infection","enrollment":320},{"nctId":"NCT06101420","phase":"PHASE3","title":"Potassium Copetitive Acid Blockers Efficacy in H.Pylori Eradication","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-01-01","conditions":"Helicobacter Pylori Eradication","enrollment":232},{"nctId":"NCT05173493","phase":"","title":"The Study About the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure","status":"COMPLETED","sponsor":"Shandong University","startDate":"2021-12-30","conditions":"Helicobacter Pylori Infection","enrollment":670},{"nctId":"NCT05728424","phase":"PHASE3","title":"One vs Two Weeks Treatment for H.Pylori Eradication A RANDOMIZED NON-INFERIORITY PLACEBO CONTROLLED TRIAL","status":"UNKNOWN","sponsor":"Aga Khan University","startDate":"2022-09-20","conditions":"Helicobacter Pylori Infection","enrollment":246},{"nctId":"NCT04810793","phase":"","title":"The Study on the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure","status":"COMPLETED","sponsor":"Shandong University","startDate":"2020-07-01","conditions":"Helicobacter Pylori","enrollment":820},{"nctId":"NCT05126121","phase":"NA","title":"Efficacy and Safety of 14-day Concomitant Therapy for Difficult-to-Treat Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Xiuli Zuo","startDate":"2021-11-20","conditions":"Helicobacter Pylori Infection","enrollment":60},{"nctId":"NCT05133193","phase":"NA","title":"Efficacy and Safety of 14-day Concomitant Therapy for Refractory Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-11-20","conditions":"Helicobacter Pylori Infection","enrollment":60},{"nctId":"NCT04991584","phase":"NA","title":"Efficacy and Safety of 14-day Concomitant Therapy for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-08-04","conditions":"Helicobacter Pylori Infection","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Vonoprazan, Amoxicillin, Levofloxacin","genericName":"Vonoprazan, Amoxicillin, Levofloxacin","companyName":"Aga Khan University","companyId":"aga-khan-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vonoprazan is a potassium-competitive acid blocker (P-CAB) that inhibits gastric acid secretion by blocking the H+/K+ ATPase enzyme. Used for Treatment of gastroesophageal reflux disease (GERD), Eradication of Helicobacter pylori.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}